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A B S T R A C T
Purpose
Estimating risk of late distant recurrence (DR) is an important goal for managing women with
hormone receptor–positive breast cancer after 5 years of endocrine treatment without recurrence.
We developed and validated a simple clinicopathologic tool (Clinical Treatment Score post–5 years
[CTS5]) to estimate residual risk of DR after 5 years of endocrine treatment.
Patients and Methods
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) data set (N = 4,735) was used to create
a prognostic score for post–5-year risk of DR. Validity of CTS5 (ATAC) was tested in the BIG 1-98 data
set (N = 6,711). Time to late DR, 5 years after finishing scheduled endocrine therapy, was the
primary end point. Cox regression models estimated the prognostic performance of CTS5 (ATAC).
Results
CTS5 (ATAC) was significantly prognostic for late DR in the ATAC cohort (hazard ratio, 2.47; 95% CI,
2.24 to 2.73; P , .001) and BIG 1-98 validation cohort (hazard ratio, 2.07; 95% CI, 1.88 to 2.28; P ,
.001). CTS5 (ATAC) risk stratification defined in the training cohort as low (, 5% DR risk, years 5 to
10), intermediate (5% to 10%), or high (. 10%) identified 43% of the validation cohort as low risk,
with an observed DR rate of 3.6% (95% CI, 2.7% to 4.9%) during years 5 to 10. From years 5 to 10,
63% of node-negative patients were low risk, with a DR rate of 3.9% (95% CI, 2.9% to 5.3%), and
24%with one to three positive nodeswere low risk, with a DR rate of 1.5% (95%CI, 0.5% to 3.8%).
A final CTS5 for future use was derived from pooled data from ATAC and BIG 1-98.
Conclusion
CTS5 is a simple tool based on information that is readily available to all clinicians. CTS5 was
validated as highly prognostic for late DR in the independent BIG 1-98 study. The final CTS5 al-
gorithm identified 42%of womenwith, 1% per-year risk of DRwho could be advised of the limited
potential value of extended endocrine therapy.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Women with estrogen receptor (ER) –positive
primary breast cancer are generally offered ad-
juvant endocrine therapy for 5 years. More than
50% of recurrences occur after that time, and
several studies have indicated that extending
treatment beyond 5 years can improve disease
outcome.1-5 However, this improvement is rela-
tively modest, and extended therapy carries a risk
of adverse effects. Few tools have been developed
for selecting patients as candidates for extended
endocrine therapy or alternatively identifying those
who might be spared such therapy. One approach
is to identify patients whose risk after 5 years is so
low that any benefit would be outweighed by
potential adverse effects.
Clinicopathologic parameters such as tumor
size, nodal status, and histopathologic grade are
routinely used to estimate risk of breast cancer
recurrence at diagnosis; we previously reported
a clinical treatment score that integrates these
factors to estimate prognosis.6 Some of these
Author affiliations and support information
(if applicable) appear at the end of this
article.
Published at jco.org on April 20, 2018.
Clinical trial information:
ISRCTN18233230, NCT00004205.
Corresponding author: Mitch Dowsett,
PhD, Ralph Lauren Centre for Breast
Cancer Research, Royal Marsden
Hospital, London, SW3 6JJ United
Kingdom; e-mail: mitch.dowsett@
icr.ac.uk.
© 2018 by American Society of Clinical
Oncology. Licensed under the Creative











© 2018 by American Society of Clinical Oncology 1
Downloaded from ascopubs.org by 86.170.186.11 on May 18, 2018 from 086.170.186.011
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
factors have been reported to be associated with risk after 5 years; for
example, we found nodal status was a powerful prognostic marker
for late recurrence,7,8 whereas tumor size and particularly grade
were less prognostic after 5 years. Recently, an overview analysis
of. 60,000 womenwith ER-positive disease, whowere scheduled to
receive 5 years of endocrine therapy and remained disease free at
5 years, reported the subsequent risk of distant recurrence.9 Even in
patients with T1N0 disease, the estimated risk of distant recurrence
between years 5 and 20 was 10% for those with low, 13% for those
with intermediate, and 17% for those with high histologic grades,
respectively. Although these data unequivocally demonstrate the
importance of these clinicopathologic factors, they include studies
from 40 years ago, possibly limiting their relevance for contemporary
patients with breast cancer. The data were presented largely as
categories (eg, T1, T2), limiting precise estimates of risk for indi-
vidual patients. Lastly, the largely tamoxifen-treated population did
not allow assessment of possible differences between tamoxifen and
aromatase inhibitors (AIs) with regard to long-term risk.
We aimed to develop and test the validity of a simple prognostic
tool to estimate risk of late distant recurrence (Clinical Treatment
Score post–5 years [CTS5]) on the basis of clinicopathologic pa-
rameters measured in virtually all patients with breast cancer at
diagnosis. We used data from the ATAC (Arimidex, Tamoxifen,
Alone or in Combination) trial10 as the training set and from the
BIG (Breast International Group) 1-98 trial as the testing set.11
PATIENTS AND METHODS
Study Populations
CTS5 (ATAC) was trained using data from the ATAC trial (Interna-
tional Standard Randomized Controlled Trial identifier ISRCTN18233230),
in which postmenopausal women with ER-positive or ER-unknown early
breast cancer were randomly assigned to receive anastrozole 1 mg per day,
tamoxifen 20 mg per day, or a combination for 5 years.10 The combination
armwas discontinued after the first report of trial results.12We included data
from women with ER-positive breast cancer randomly assigned to receive
anastrozole alone or tamoxifen alone, who were distant recurrence free after
5 years of follow-up and for whom all clinicopathologic data were available
(N = 4,735; Appendix Fig A1, online only). Median follow-up was 9.8 years.
Data fromBIG 1-98 (ClinicalTrials.gov identifier NCT00004205)was used to
validate CTS5 (ATAC). BIG 1-98 initially (1998 to 2000) randomly assigned
postmenopausal women with hormone receptor–positive early-stage breast
cancer to receive 5 years of letrozole 2.5 mg per day or tamoxifen 20 mg per
day. Later (1999 to 2003), sequential therapy was also randomly assigned
(2 years of letrozole followed by 3 years of tamoxifen or opposite
sequence).11,13 Median follow-up was 8.1 years. For this analysis, all women
were included who were distant recurrence free at 5 years and for whom all
clinicopathologic data were available (N = 6,711; Appendix Fig A1). For both
trials, women were included in the analysis regardless of whether they re-
ceived chemotherapy.
Prognostic value of the following variables for post–5-year (late)
distant recurrence was determined by univariable Cox regression analyses:
nodes, tumor size (in millimeters), grade (1, 2, or 3), age at start of
endocrine therapy (years), and type of assigned endocrine treatment. Type
of endocrine treatment was not significant for late distant recurrence in
univariable analyses and not included in the final model. The log hazard was
almost linear for five nodal status groups (negative, one positive, two to three
positive, four to nine positive, and . nine positive) but not for continuous
tumor size alone. Therefore, a negative quadratic term was introduced, and
tumor size was capped at 30 mm, where risk plateaued. The final CTS5
(ATAC) model included age (continuous), tumor size (continuous), quadratic
tumor size, nodal status (five groups: 0, negative; 1, one positive; 2, two to
three positive; 3, four to nine positive; and 4, . nine positive), and grade
(three groups: 1, low; 2, intermediate; and 3, high) and is given by:
CTS5 (ATAC) = 0.471 3 nodes + 0.980 3 (0.164 3 size 2 0.003 3
size2 + 0.312 3 grade + 0.03 3 age)
A shrinkage factor of 0.980 for the nonnodal part of the score was cal-
culated using a nested Cox model14 and applied to allow for the small
amount of overfitting. Separate models developed for patients receiving
chemotherapy or not did not perform significantly better for either group
than a single model including all patients (data not shown).
Statistical Analyses
Analyses were performed according to a prespecified analysis plan,
approved by both trial groups, and are summarized here. Full details are
provided in the Appendix (online only). The primary end point was time
to distant recurrence, defined as metastatic disease, excluding contralateral
disease, and locoregional and ipsilateral recurrences. The end point was
censored at last follow-up visit or death before distant recurrence such that
risk is a pure risk calculation ignoring deaths.
Cox proportional hazards models were used to create the model in
ATAC, and the CTS5 (ATAC) score was tested in BIG 1-98. Likelihood ratio
statistics (LR-x2) and Kaplan-Meier survival estimates with corresponding
95%CIs were used to determine the prognostic performance of CTS5 (ATAC)
in BIG 1-98. The 5- to 10-year distant recurrence risk groups were determined
in ATAC and defined as: low risk, , 5%; intermediate risk, 5% to 10%; and
Table 1. Demographic and Clinical Characteristics According to Trial of Patients








Age, years , .001
Median 64 61
IQR 57-71 56-67
Nodal status (No. of positive nodes) , .001*
Negative 3,219 (68.0) 4,090 (60.9)
1 643 (13.6) 1,164 (17.3)
2-3 523 (11.1) 780 (11.6)
4-9 277 (5.9) 506 (7.5)
9+ 73 (1.5) 171 (2.6)
Grade .007*
Well 1,149 (24.3) 1,524 (22.7)
Intermediate 2,387 (50.4) 3,828 (57.0)
Poor 1,199 (25.3) 1,359 (20.3)
Tumor size, mm .44*
, 10 864 (19.7) 1,172 (17.5)
10-20 2,356 (49.8) 3,206 (47.8)
20-30 1,028 (21.7) 1,571 (23.4)
. 30 487 (10.3) 762 (11.4)
Chemotherapy 923 (19.5) 1,627 (24.2) , .001
Treatment
Tamoxifen 5 years 2,374 (50.1) 1,989 (29.6)
Anastrozole or letrozole 5 years 2,361 (49.9) 2,042 (30.4)
Letrozole 2 years and tamoxifen
3 years
— 1,335 (19.9)
Tamoxifen 2 years and letrozole
3 years
— 1,345 (20.0)
Distant recurrence (. 5 years) 330 (7.0) 370 (5.5) .014
Annual rate, % 0.79 0.66
95% CI, % 0.71 to 0.88 0.60 to 0.73
NOTE. Random assignment indicates start of adjuvant endocrine therapy.
Abbreviations: ATAC, Arimidex, Tamoxifen, Alone or Combination; BIG, Breast
International Group; IQR, interquartile range.
*P trend.
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high risk, . 10%. To compare the prognostic performance of CTS5 (ATAC)
between ATAC and BIG 1-98 trials, CTS5 (ATAC) was normalized to have
unit variance, and hazard ratios (HRs) and associated 95%CIs were estimated
from Cox models. All statistical analyses were two sided, and P , .05 was
regarded as statistically significant. We compared the newly developed CTS5
(ATAC) with the published CTS (termed CTS0 here) developed for estimating
prognosis from the time of disease presentation.6 All analyses were performed
with STATA software (version 13.1; College Station, TX).
RESULTS
The ATAC training set and the BIG 1-98 test set consisted of 4,735
and 6,711 postmenopausal patients, respectively, assigned to re-
ceive 5 years of endocrine therapy (Table 1). Women in the ATAC
cohort were significantly older by an average of approximately
3 years and hadmore node-negative disease (68% v 61%) andmore
grade 3 tumors (25% v 20%), and fewer women received adjuvant
chemotherapy compared with women in the BIG 1-98 set (19.5% v
24.2%). Tumor size was similar between the two trials. In the
training set, 330 (7.0%) late distant recurrences were recorded,
with an annual hazard rate of 0.79% (95% CI, 0.71% to 0.88%). In
BIG 1-98, a total of 370 (5.5%) late distant recurrences occurred,
with an annual hazard rate of 0.66% (95% CI, 0.60% to 0.73%),
which was significantly lower than in ATAC (P = .014; Table 1).
Training Set (ATAC)
Appendix Table A1 (online only) shows the comparisons of
the published CTS06 with CTS5 (ATAC) for prediction of late distant
recurrence between years 5 and 10. CTS5 (ATAC) provided sig-
nificantly more prognostic information compared with CTS0 (CTS5
[ATAC]: LR-x2 = 308.6 [5 df]; CTS0: LR-x2 = 285.0 [9 df]), and
larger effect sizes were observed (HR, 2.47 v 2.04, respectively). CTS5
(ATAC) was slightly more prognostic in chemotherapy-free women
compared with those who received chemotherapy (HR, 2.50; 95%
CI, 2.22 to 2.81 v 2.39; 95%CI, 1.94 to 2.95), but the interactionwith
chemotherapy use was not significant (P = .76).
The prognostic value of CTS5 (ATAC) for risk of distant
recurrence (6 95% CI) between years 5 and 10 is shown in
Figure 1A for the whole population and in Figure 1B for node-
positive and node-negative populations separately. Cutoffs in the
ATAC population to separate low-, intermediate-, and high-risk
populations were 4.35 and 5.02, respectively (Fig 1A). As expected,
most but not all low-risk patients were node negative, and con-
versely, most high-risk patients were node positive (Fig 1B).
Overall, 42.0% were categorized as low risk, 31.3% as in-
termediate risk, and 26.7% as high risk for late distant recurrence
(Table 2). Those categorized as low risk had a mean 5- to 10-year
distant recurrence risk of 2.5% (95% CI, 1.8% to 3.4%), as
compared with 7.7% (95%CI, 6.3% to 9.5%) for intermediate-risk
and 20.3% (95% CI, 17.2% to 24.0%) for high-risk groups (Fig 2).
Those at intermediate or high risk had a 3.42-fold (95% CI, 2.37-
to 4.95-fold) or 9.43-fold (95% CI, 6.71- to 13.25-fold), re-
spectively, higher risk of late distant recurrence than the low-risk
group. Notably only two of 133 patients with one to three positive
nodes and categorized as low risk had a distant recurrence between
years 5 and 10 (Table 2). Virtually all patients with$ four positive
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Fig 1. Predicted distant recurrence (DR) risk in years 5 to 10 since random assignment (start of adjuvant endocrine therapy) for ATAC (Arimidex, Tamoxifen, Alone or
Combination) trial (A) overall population and (B) node-negative and node-positive patients. Solid vertical lines indicate cutoff points for risk groups. CTS5, Clinical Treatment
Score post–5 years.
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patients with two or three positive nodes had risk categorized as
low or intermediate, whereas 42.9% with one positive node were
categorize as high risk. Only 57.7% of node-negative patients were
categorized as low risk.
A total of 77 patients experienced local recurrence but no distant
recurrence in years 0 to 5, with CTS5 (ATAC) ranking most as in-
termediate or high risk. Among these 77, CTS5 (ATAC) predicted 24.3
distant recurrences, and 25 were observed. Exclusion of these 77
patients marginally increased the HR for one standard deviation
change, from2.47 (95%CI, 2.24 to 2.73) to 2.53 (95%CI, 2.26 to 2.82).
Validation Set (BIG 1-98)
CTS5 (ATAC) performed non-significantly better in the vali-
dation BIG 1-98 cohort than CTS0 (CTS5 [ATAC]: HR 2.07; 95%CI,
1.88 to 2.28; LR-x2 = 212.1 [1 df] v CTS0: HR 1.84; 95% CI, 1.70 to
1.98; LR-x2 = 214.9 [1 df]). CTS5 (ATAC) was significantly prog-
nostic in women who did not receive chemotherapy (HR, 2.20; 95%
CI, 1.96 to 2.47; P , .001; LR-x2 = 168.7 [1 df]) and more so when
compared with those who did (HR, 1.76; 95% CI, 1.46 to 2.13; P ,
.001; LR-x2 = 34.7 [1 df]; Appendix Table A1), but the interaction
with chemotherapy was not statistically significant (P = .06).
The number of observed distant recurrences was compared
with those expected by CTS5 (ATAC) in deciles of risk for node-
negative and node-positive patients, separately (Figs 3A and 3B). In
each case, there were no significant differences between the observed
and expected numbers for any of the deciles. The correlation (r)
between the observed versus expected numbers across the deciles
was 0.89 for node-negative and 0.95 for node-positive groups. Using
CTS0, a number of deciles showed significant x2 values (Appendix
Fig A2, online only), and the r values were also lower, at 0.78 and
0.87, respectively. Concordance between the estimated and actual
distant recurrence rates was also shown to be better with CTS5 using
the Goran-Heller C-index (CTS5 [ATAC], 0.678; CTS0, 0.656).
We used predefined cutoff points of 4.35 and 5.02 from ATAC
to determine risk groups for late distant recurrence in BIG 1-98
(Figs 1A and 1B). These cut points intersected the risk curves for
BIG 1-98 at 5.4% and 9.9% for node-negative patients and 5.5%
and 9.5% for node-positive patients, respectively, and therefore
were strongly validated by this test set. The distribution of patients
in low-, intermediate-, and high-risk groups was also similar in the
BIG 1-98 data set to that observed in the training set (Table 2). The
mean 5- to 10-year distant recurrence risk of patients in BIG 1-98
in those three categories was 3.6% (95% CI, 2.7% to 4.9%), 6.9%
(95% CI, 5.6% to 8.5%), and 17.3% (95% CI, 14.8% to 20.1%),
respectively (Table 2; Fig 2). Thus, for each category, the actual mean
risk for each category fitted well with that of the predicted risk. The
curves for node-negative and node-positive women were almost
identical in the CTS5 (ATAC) regions of overlap in BIG 1-98.
Table 2. Distribution of Risk Categories in the ATAC and BIG 1-98 Cohorts According to Tumor Size, Grade, and Nodal Involvement
Characteristic
No. (%)
Total No.Low Risk Intermediate Risk High Risk
ATAC
Total 1,989 (42.0) 1,484 (31.3) 1,262 (20.7) 4,735
Size, mm
, 10 808 (40.6) 41 (2.8) 15 (1.2) 864
10-20 1,082 (54.4) 872 (58.8) 402 (31.9) 2,356
. 20 99 (5.0) 571 (38.5) 845 (67.0) 1,515
Grade
Well 806 (70.1) 235 (20.6) 108 (9.4) 1,149
Intermediate 952 (39.9) 861 (36.1) 574 (24.0) 2,387
Poor 231 (19.3) 388 (32.4) 580 (48.4) 1,199
Nodal involvement (No. of positive nodes)
None 1,856 (57.7) 1,138 (35.4) 225 (7.0) 3,219
1 112 (17.4) 255 (39.7) 276 (42.9) 643
2-3 21 (4.0) 84 (16.1) 418 (79.9) 523
4-9 0 6 (2.2) 271 (97.8) 277
. 9 0 1 (1.4) 72 (98.6) 73
BIG 1-98
Total 2,861 (42.6) 2,136 (31.8) 1,714 (25.5) 6,711
Size, mm
, 10 1,081 (37.8) 65 (3.0) 26 (1.5) 1,172
10-20 1,585 (55.4) 1,103 (51.6) 518 (30.2) 3,206
. 20 195 (6.8) 968 (45.3) 1,170 (68.3) 2,333
Grade
Well 1,077 (70.7) 308 (20.2) 139 (9.1) 1,524
Intermediate 1,575 (41.1) 1,301 (34.0) 952 (24.9) 3,828
Poor 209 (15.4) 527 (38.8) 623 (45.8) 1,359
Nodal involvement (No. of positive nodes)
None 2,555 (62.5) 1,398 (34.2) 137 (3.3) 4,090
1 277 (23.8) 541 (46.5) 346 (29.7) 1,164
2-3 27 (3.5) 175 (22.4) 578 (74.1) 780
4-9 2 (0.4) 21 (4.2) 483 (95.5) 506
. 9 0 1 (0.6) 170 (99.4) 171
Abbreviations: ATAC, Arimidex, Tamoxifen, Alone or Combination; BIG, Breast International Group.
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Significant separation between low- versus intermediate-risk
groups (HR, 2.19; 95% CI, 1.61 to 2.98) and low- versus high-risk
groups (HR, 5.33; 95% CI, 4.02 to 7.07) was observed (Fig 2).
Notably, only four of 304 patients with one to three positive nodes
and categorized as low risk had a recurrence between years 5 and 10.
As with the ATAC data set, in BIG 1-98, virtually all patients with
$ four positive nodes were categorized as high risk (Table 2). The
distribution of patients in the risk categories across histologic grades
and nodal categories was similar between ATAC and BIG 1-98.
Again, approximately one fifth of patients with two or three positive
nodes had risk categorized as low or intermediate, but a somewhat
smaller proportion of patients with one positive node were categorize
as high risk (29.7% v 42.9%). In BIG 1-98, 62.5% of node-negative
patients were categorized as low risk, compared with 57.7% in ATAC.
Combined ATAC and BIG 1-98 Sets
To increase the precision of the risk estimates, we combined
the ATAC and BIG 1-98 data sets such that new coefficients were
fitted using the same variables as in the training or validation
cohort. The final CTS5 is represented by the following model:
CTS5 = 0.438 3 nodes + 0.988 3 (0.093 3 size 2 0.001 3
size2 + 0.375 3 grade + 0.017 3 age)
The relationship between the final CTS5 and risk of distant recurrence
is shown in Figure 4, with a table of CTS5 values that relate to one-
unit intervals of distant recurrence risk. New cutoff points for low-
(CTS5 , 3.13), intermediate- (3.13 to 3.86), and high-risk (. 3.86)
groups were derived from this final model. An example of the cal-
culation of CTS5 and the associated risk estimate is given in Figure 4.
DISCUSSION
Over the last three decades, there have been major increases in
invasive breast cancer incidence inWestern countries; in the United
States, it was estimated that. 250,000 women would be diagnosed
with invasive breast cancer in 2017,15 with a large majority of cases
localized to the breast. Approximately 80% of patients are now
diagnosed as ER positive, and almost all of these are prescribed
5 years of adjuvant endocrine therapy. Although such treatment
markedly reducesmortality (eg, by approximately 30%with 5 years
of tamoxifen and approximately 40% with an AI in post-
menopausal women), recurrences continue to occur after the
5-years treatment ends. The observation that these events can be
decreased by continued treatment1,2,16 means that decisions about
whether to continue with therapy at 5 years are at the forefront of
patient management at that time. We expect that the CTS5 tool
reported and validated here will prove helpful to oncologists and
patients in making a decision about continued treatment. The
integration of clinical pathologic features that are measured in all
patients at diagnosis should mean that risk is calculable at little
expense globally; the table in Figure 4 will allow a direct readout,
and an online tool will be provided to facilitate estimates of
continuous risk.
Strengths of the study include its use of two large sets of
registration-standard randomized clinical trial data with detailed
clinical follow-up for 10 years. The ATAC training set included
the AI anastrozole as well as tamoxifen as adjuvant treatment, and
although the specific endocrine adjuvant therapy did not feature
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Fig 2. Kaplan-Meier curves and 5- to 10-year
distant recurrence (DR) rates since random as-
signment for the overall population according to trial
(solid lines, ATAC [Arimidex, Tamoxifen, Alone or
Combination]; dashed lines, BIG [Breast International
Group] 1-98).
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valid for both tamoxifen- and AI-treated patients. This is consistent
with the overview analysis of AIs versus tamoxifen.17 Median 5-year
follow-up for the two trials combined occurred approximately
12 years ago. Therefore, it is possible that our risk estimates may not
accurately reflect those of current patients reaching 5 years. How-
ever, the only major change to the management of primary ER-
positive breast cancer since the completion of recruitment to ATAC
and BIG 1-98 has been the introduction of trastuzumab for patients
with human epidermal growth factor receptor 2–positive disease.
CTS5 should be applied with caution in such patients until validated
specifically for that population. All patients in the two cohorts were
postmenopausal at diagnosis. Although risk of distant recurrence
post–5 years has been reported to be similar across age groups, other
than for the small group of patients diagnosed at age, 35 years,9 the
present algorithm cannot be extended to premenopausal patients
without further validation.
Neither trial collected complete information on the use of ex-
tended adjuvant endocrine therapy. However, the first significant data
supporting the use of an AI after tamoxifen1 emerged close to the end
of the treatment period for the trials, and we estimate that , 1% of
tamoxifen-treated patients in ATAC and , 5% in BIG 1-98 received
such extended therapy. This would be expected to have minimal
impact on our estimates of risk when extended therapy is not used.
Also similar to the report by the Early Breast Cancer Trialists’
Collaborative Group, we found that whether patients had received
chemotherapy at presentation had no significant impact on re-
sidual risk of recurrence when taking the other factors into ac-
count. This may relate in part to the observation that the bulk of
the benefit from adjuvant chemotherapy is shown over the first
5 years of follow-up.18
The categories of low, intermediate, and high risk were chosen to
closely parallel those defined by several molecular profiling tools for
managing patients with ER-positive breast cancer.19-21 However,
those tools are applied immediately after surgery, largely in making
the decision of whether to administer adjuvant chemotherapy; what is
considered low or high risk in that setting may not be the same when
considering the appropriateness of extended adjuvant therapy. In



















Decile Observed Expected No. of Patients
1 4 4.4 410 .036
2 7 6.7 414 .013
3 4 8.2 405 2.15
4 14 9.9 409 1.69
5 15 11.7 410 .93
6 10 13.3 406 .81
7 15 15.5 411 .016
8 16 17.8 409 .18
9 27 21.3 416 1.52



















Decile Observed Expected No. of Patients
1 4 4.1 263 .002
2 8 10.9 262 .77
3 16 13.5 262 .46
4 17 16.1 264 .05
5 17 18.4 260 .11
6 26 21.8 262 .81
7 26 25.1 262 .032
8 38 29.9 262 2.19
9 28 38.2 263 2.72





Fig 3. Observed versus expected number of events and x2 values in the BIG (Breast International Group) 1-98 trial according to deciles of Clinical Treatment Score post–5
years (ATAC [Arimidex, Tamoxifen, Alone or Combination]) for (A) node-negative and (B) node-positive patients. None of the x2 were statistically significant.
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or ceasing endocrine therapy at 5 years are likely to vary markedly, the
use of a continuous risk estimate from CTS5 is likely to be more
informative than the categorical estimates (ie, low, intermediate, and
high) used here for illustrative and comparative purposes.
The agreement between the ATAC and BIG1-98 data was
almost complete within the low- and intermediate-risk categories
but somewhat less beyond the intermediate/high cutoff. Thus, the
instrument may be used with greatest confidence in defining 5- to
10-year distant recurrence risk when, 10% and will be of greatest
use in assessing the potential value of extended therapy on the basis
of risk estimates below that level.
Our report deals only with clinicopathologic profiles. Mul-
tigene expression profiles have significantly increased the ability to
predict distant recurrence over 10 years after diagnosis in ER-
positive breast cancer.22 Several of these signatures, such as the
Oncotype Dx recurrence score,23 PAM50-based Prosigna risk
of recurrence score,19,24 Breast Cancer Index,25,26 EndoPredict
test,20,27,28 and Netherlands Cancer Institute 70-gene signature,29
are commercially available and endorsed by several guidelines.30-33
Although a number of them estimate risk of late as well as early
recurrence, these tests were developed to manage patients with
breast cancer at diagnosis and have not been calibrated for ap-
plication 5 years after diagnosis. Over the first 10 years of follow-
up, clinicopathologic and molecular factors have nearly completely
independent prognostic value, and their optimal use for prognosis
requires their integration.34 It is near certain that the same is true
for the 5- to 10-year period. CTS5 provides a straightforward
starting point for combining with molecular scores.
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Appendix
The primary end point was time to distant recurrence (DR). DR was defined as metastatic disease, excluding contralateral
disease, and locoregional and ipsilateral recurrences. The end point was censored at last follow-up visit or death before DR such that
risk is a pure risk calculation ignoring deaths.
Cox proportional hazards models were used to create the model in ATAC (Arimidex Tamoxifen Alone or Combination), and
the Clinical Treatment Score post–5 years (CTS5; ATAC) was tested in BIG (Breast International Group) 1-98. A shrinkage factor of
0.980 for the nonnodal part of the CTS5 (ATAC) score had been calculated during its derivation using a nested Cox model14and
applied to allow for the small amount of overfitting. We estimated the shrinkage factor with the following equation:
g = ([model x22 df]/model x2)1/2where model x2 is the likelihood ratio x2 statistic for testing all predictors, and df is degree of
freedom.
To define the relation between CTS5 and 5- to 10-year DR risk, the logarithm of the baseline cumulative hazard function was
fitted. Baseline risk at 5 years was calculated using the stcox/basesurv command in STATA (College Station, TX) to implement the
Breslow method. Five- to 10-year DR risk was then calculated for each participant by adjusting the baseline risk:
risk(5-10 years) = 1 2 ([baseline risk]linear prediction CTS5)
Proportional assumptions were verified using Schoenfeld residuals.
Likelihood ratio x2 statistics and Kaplan-Meier survival estimates with corresponding 95% CIs (calculated from the standard
error of the cumulative hazards on the basis of a normal approximation) were used to determine the prognostic performance of
CTS5 (ATAC) in BIG 1-98. The risk of DR of events for individual patients in BIG 1-98 was estimated using CTS5 or the published
Clinical Treatment Score (CTS0) and the expected risk compared with the observed events in deciles of expected risk. The observed
and expected numbers were compared by the x2 test. Overall agreement was assessed by calculating the correlation coefficient across
the deciles. Concordance between expected and actual outcomes was also calculated by computing the Goran-Heller C-index.
The 5- to 10-year DR risk groups were determined in ATAC and defined as: low-risk group, , 5%; intermediate-risk group,
5%-10%; and high-risk group, . 10%. To compare the prognostic performance of CTS5 (ATAC) between ATAC and BIG 1-98
trials, CTS5 (ATAC) was normalized to have unit variance, and the hazard ratios and associated 95% CIs were estimated from Cox
models. All statistical analyses were two sided, and P , .05 was regarded as statistically significant. We also compared the newly
developed CTS5 (ATAC) with CTS0, which was developed for estimating prognosis from the time of disease presentation6 to
determine whether an improved prognostication for late DR had been achieved. All analyses were performed with STATA software
(version 13.1).
The final model was fitted on the combined ATAC and BIG 1-98 data sets to give an overall calibration of CTS5. Therefore, new
coefficients were fitted in the combined data set but using the same variables as in the training or validation cohort (ie, five nodal
groups, continuous age, continuous size, and three grade groups).
Table A1. Comparison of Prognostic Performance of CTS06 and CTS5 (ATAC) According to Trial
Score
ATAC (n = 4,735) BIG 1-98 (n = 6,711)
HR* (95% CI) LR-x2† HR* (95% CI) LR-x2‡
CTS06 2.04 (1.88 to 2.21) 285.0 1.84 (1.70 to 1.98) 214.9
CTS5 (ATAC) 2.47 (2.24 to 2.73) 308.6 2.07 (1.88 to 2.28) 212.1
No chemotherapy§ 2.50 (2.22 to 2.81) 215.6 2.20 (1.96 to 2.47) 168.7
Chemotherapyk 2.39 (1.94 to 2.95) 73.2 1.76 (1.46 to 2.13) 34.7
Abbreviations: ATAC, Arimidex, Tamoxifen, Alone or Combination; BIG, Breast International Group; CTS0, published Clinical Treatment Score; CTS5, Clinical Treatment
Score post–5 years; HR, hazard ratio, LR, likelihood ratio.
*HR for a change in one standard deviation.
†9 df for CTS0; 5 df for CTS5 (ATAC).
‡1 df.
§n = 3,812 for ATAC; n = 5,084 for BIG 1-98.
kn = 923 for ATAC; n = 1,627 for BIG 1-98.
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Dowsett et al
Downloaded from ascopubs.org by 86.170.186.11 on May 18, 2018 from 086.170.186.011
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.




DR free at 5 years
(n = 6,711)
(DR: n = 370)







(DR: n = 256)
Chemotherapy
(n = 1,627)
































(DR: n = 230) 
Chemotherapy
(n = 923)







DR free at 5 years
(n = 4,735)
(DR: n = 330)
Fig A1. CONSORT diagram according to trial. ATAC, Arimidex, Tamoxifen, Alone or Combination; BIG, Breast International Group; DR, distant recurrence.
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1 6 7 452 .14
2 5 9.4 461 2.06
3 4 7 320 1.29
4 16 12.8 480 .80
5 10 11.8 404 .27
6 14 12.4 402 .21
7 18 13.6 397 1.42
8 12 14.2 364 .34
9 28 18.1 411 5.41
10 22 28.7 399 1.56





















1 5 11 320 3.27
2 9 13.9 309 1.73
3 7 8.7 170 .33
4 16 14.9 271 .08
5 23 17.3 267 1.88
6 19 16.9 238 .26
7 37 23.3 260 8.06
8 23 31.6 269 2.34
9 47 37.5 255 2.41
10 49 59.9 262 1.98





















Fig A2. Observed versus expected number of events and x2 values in the BIG (Breast International Group) 1-98 trial according to deciles of published Clinical Treatment
Scores (CTSO) for (A) node-negative and (B) node-positive patients. p , 0.05 when x2 . 3.84.
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